3.16 USD
▲+0.39+3.95%
盘后 2.99 -1.60%
2026-08-03
市值
$200.20M
市盈率
—
EPS
-1.30
股息率
—
52 周区间
0.97 – 5.55
成交量
926.18K
Beta
1.32
目标价
6.75
52W 低 0.9752W 高 5.55
价格走势
公司简介
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-o...